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Antibody subclasses exhibit extensive polymorphisms (allotypes) that could potentially 
impact the quality of HIV-vaccine induced B cell responses. Allotypes of immunoglobulin 
(Ig) G1, the most abundant serum antibody, have been shown to display altered func-
tional properties in regard to serum half-life, Fc-receptor binding and FcRn-mediated 
mucosal transcytosis. To investigate the potential link between allotypic IgG1-variants 
and vaccine-generated humoral responses in a cohort of 14 HIV vaccine recipients, we 
developed a novel protocol for rapid IgG1-allotyping. We combined PCR and ELISA 
assays in a dual approach to determine the IgG1 allotype identity (G1m3 and/or G1m1) of 
trial participants, using human plasma and RNA isolated from PBMC. The IgG1-allotype 
distribution of our participants mirrored previously reported results for caucasoid pop-
ulations. We observed elevated levels of HIV gp140-specific IgG1 and decreased IgG2 
levels associated with the G1m1-allele, in contrast to G1m3 carriers. These data suggest 
that vaccinees homozygous for G1m1 are predisposed to develop elevated Ag-specific 
IgG1:IgG2 ratios compared to G1m3-carriers. This elevated IgG1:IgG2 ratio was further 
associated with higher FcγR-dimer engagement, a surrogate for potential antibody- 
dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis 
(ADCP) function. Although preliminary, these results suggest that IgG1 allotype may 
have a significant impact on IgG subclass distribution in response to vaccination and 
associated Fc-mediated effector functions. These results have important implications 
for ongoing HIV vaccine efficacy studies predicated on engagement of FcγR-mediated 
cellular functions including ADCC and ADCP, and warrant further investigation. Our 
novel allotyping protocol provides new tools to determine the potential impact of IgG1 
allotypes on vaccine efficacy.
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inTrODUcTiOn
Antibodies are generally accepted to contribute to vaccine induced protection against many infec-
tious diseases including HIV (1). However, the involvement of different antibody classes or subclasses 
is less clear, where their different structural properties affect functional immunity. While antibody 
binding fragments (Fabs) are critical to determining binding specificity and neutralization, the Fc 
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domain is the primary determinant for a wide spectrum of immu-
nological functions mediated by the engagement of Fc-gamma 
receptors (FcγR) on a range of effector cells. These functions are 
regulated during an immune response through Immunoglobulin 
(Ig) subclass composition tailoring the selective interaction with 
FcγR on effector immune populations. Indeed, it has been sug-
gested that Ig subclass composition may influence a wide range 
of Fc-mediated effector functions including antibody-dependent 
cellular cytotoxicity (ADCC) and antibody-dependent cellular 
phagocytosis (ADCP) (2). In this respect Fc-mediated effector 
functions likely augment the potency of broadly neutralizing 
antibodies (3) and are critical to the function of non-neutralizing 
antibodies. The observed modest efficacy of the RV144 HIV 
vaccine trial showing vaccine elicited protection in the absence 
of neutralizing antibodies (4) has driven an intense interest in 
the role of FcγR effector functions in protection and control of 
HIV infection (5, 6). Here the antibody subclass distribution is 
likely to play a critical role where IgG1/IgG3 interact efficiently 
with most FcγR, while IgG2/IgG4 show reduced affinity for 
many FcγR. Indeed, divergent antibody subclass profiles have 
been associated with variable antibody effector functions among 
HIV-1 controllers, where levels of HIV-specific IgG1/3 were the 
major distinguishing factor (7), while IgG2/IgG4 HIV specific 
antibodies were associated with poorer overall antibody activity 
(8). In this respect, inter-individual variation in the antibody 
subclass response profiles to HIV-1 infection and/or vaccination 
provides significant challenges in the development of a globally 
effective vaccine.
In addition to sequence diversity of variable Fab domains and 
isotypic variation, IgG-subclass antibodies have been shown to 
exhibit polymorphic epitopes (IgG-allotypes), which can differ 
between individuals and ethnic groups (2). Inherited in a codomi-
nant Mendelian fashion, IgG-heavy chain allotypes are designated 
as natural genetic marker (Gm) together with the antibody sub-
class (e.g., G1m) and the allotype number (e.g., G1m3 or G1m1) 
(9). So far, a total of 4 G1m human allotypes: G1m17, G1m3, 
G1m1, and G1m2; two G1m alloallotypes: G1m27 and G1m28; 
and two G1m isoallotypes: nG1m17 and nG1m1 have been 
identified via serological typing (10). These define 7 G1m alleles: 
G1m17,1; G1m3; G1m17,1,27; G1m17,1,28; G1m17,1,27,28; 
G1m17,1,2; and G1m3,1; where the G1m1 allotype is common 
to all alleles except G1m3. The prevalence of these alleles broadly 
differs according to European, African or Asian ancestry. Most 
Gm allotypes are located in the Fc-region (CH2 or CH3) of 
antibodies, with the exception of G1m3 which is linked to amino 
acid changes in the CH1-region: expressing Arg rather than Lys 
at position 120 (2, 10). G1m3 also expresses unique amino acids 
at positions 356 (Glu) and 358 (Met) in CH3 as opposed to Asp/
Leu common to all G1m1 allotypes. While allotypes are encoded 
by one given Ig gene, some amino acid variations can be found in 
antibody chains of other isotypes (isoallotypes). For example, the 
amino acid residue Arg120, which corresponds to G1m3, is also 
found in antibodies belonging to the IGHG3 and IGHG4 allele 
family (10, 11).
Prior work has linked Gm allotypes in the Ig constant heavy 
G chain (IGHG) to augmented antibody responses against 
certain diseases (12–15). For example, IgG antibody responses 
against the hepatitis C virus envelope proteins E1E2 in a cohort 
of infected subjects with GM 1,17 5,13 and KM 1 phenotypes 
exhibit fourfold higher levels of E1E2-specific antibodies (13). 
Another study showed that IgG1 antibody levels to malaria 
vaccine-antigens were significantly higher in subjects with the 
GM 3 23 5,13,14 phenotype when compared to subjects lacking 
this phenotype (16).
Similar trends have been reported for IgG-subclass and 
specificity profiles in a cohort of elite HIV-1 controllers where 
HIV-specific IgG1 levels correlated with Fc-dependent effector 
functions and total plasma IgG1. Subsequently, it was argued 
that Gm allotypes could be responsible for variations in IgG1-
concentrations and it was suggested that future studies should 
incorporate Gm allotyping protocols to account for this pos-
sibility (7). Furthermore, previous studies have demonstrated 
the involvement of Gm alleles in ADCC of cancer cells (17, 18). 
Taken together these studies indicate that Gm allotypes impact 
on antibody functionality (19) and provided a strong rationale for 
investigating the impact of IgG1-allotypes on the magnitude and 
functionality of vaccine-induced IgG-subclasses responses in the 
context of an HIV-vaccine trial.
Traditionally Gm phenotype has been determined via hemag-
glutination inhibition assays (HAI) using anti-Rh IgG antibodies 
of known allotypy, and polyclonal IgG of a selected allotype-spec-
ificity (e.g., antihuman G1m3). However, access to such reagents 
can be rate limiting and the approach is less amenable to high 
volume screening. Given the dominant role of IgG1 responses to 
HIV-1 envelope immunogens (20), we sought to determine the 
impact of IgG1-allotypy on the magnitude of induced responses. 
Here, we combined PCR and ELISA assays in a dual approach to 
determine the IgG1 allotype identity (G1m3 and/or G1m1) of 
clinical trial participants, using human plasma and RNA isolated 
from PBMC. Subsequently, the distribution of IgG1-allotypes 
formed the framework for assessing the effect of IgG1-allotypes 
on the magnitude and functionality of vaccine-induced antibody 
responses. Understanding how IgG1 allotype influences IgG 
subclass distribution in response to vaccination may prove an 
important consideration in the design and evaluation of vaccines 
strategies across ethnic groups.
MaTerials anD MeThODs
hiV Vaccine Trials
This study mainly builds upon findings from the previously pub-
lished X001 clinical trial (21), registered at http://ClinicalTrials.
gov under no. NCT01966900, EudraCT 2013-001032-22. In 
brief, a recombinant clade C HIV-1 envelope gp140 protein 
(CN54gp140) produced by Polymun Scientific (Klosterneuburg, 
Austria) to GMP specification, which has been reported to be 
immunogenic in a number of preclinical and clinical studies 
(22, 23), was used. The vaccine antigen CN54gp140 was admin-
istered intramuscularly into the deltoid muscle of the upper arm 
at a dosage of 100 µg CN54gp140 formulated with 5 µg GLA-AF 
[Glucopyranosyl Lipid A—Aqueous Formulation, Infectious 
Disease Research Institute, Seattle, USA (24)] in a total volume 
of 0.4 ml at weeks 0, 4, and 8 with a boost inoculation with the 
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same material at either month 6 or 12. The trial was performed 
at the NIHR/Wellcome Trust Imperial Clinical Research Facility, 
Imperial College, London. The trial population was predominantly 
Caucasian, although subject ethnicity was not recorded as part of 
the trial. Samples were also obtained from the MUCOVAC2 study 
(23) registered with the UK Clinical Research Network (UKCRN) 
Number 11679, EudraCT 2010-019103-27. In brief, recombinant 
CN54gp140 was administered by intramuscular (IM), intranasal 
(IN), or intravaginal routes of administration in HIV negative 
female volunteers. Sera was obtained for this study from subjects 
receiving IM immunizations administered at the same dosage as 
the X001 trial (100 μg with 5 μg GLA-AF) with the same schedule 
(0, 4, and 8 weeks). The trial population was also predominantly 
Caucasian.
ethics statement
The clinical trials generating serum and PBMC samples were 
conducted in compliance with UK Clinical Trial Regulations and 
any amendments, which include compliance with the principles 
of Good Clinical Practice, and the study abided by the principles 
of the Declaration of Helsinki. All volunteers provided written 
informed consent to participate in the trials on the basis of 
appropriate information and with adequate time to consider the 
information and discuss the trial with the Principal Investigators 
or their delegate. The trial proposal, the trial-specific information 
provided to volunteers, the consent form and substantial proto-
col amendments (if applicable) were reviewed by a recognized 
Research Ethics Committee and by the Medicines and Healthcare 
products Regulatory Authority (see EudraCT numbers above). 
All volunteers were made aware that they were free to withdraw 
without obligation at any time and that such an action would not 
adversely affect any aspect of their medical care or legal rights.
PBMc isolation
PBMC were isolated using density gradient separation from 
heparinized whole blood, used fresh (within 8 h of blood collec-
tion) or frozen in a mixture of fetal bovine serum (Sigma-Aldrich, 
St. Louis, MO, USA) and DMSO at a 90:10 ratio using a Kryo 
560-16 rate controlled freezer (Planer, Sunbury-On-Thames, 
UK). PBMC were stored in vapor phase liquid nitrogen.
Determining the igg1-allotype identity
Human RNA was isolated from PBMC with the RNeasy Mini Kit 
for RNA (Qiagen, UK) and transcribed into cDNA via oligo(dT)18 
primers, using the maxima first strand cDNA synthesis kit (Cat: 
K1672, Thermo Scientific, UK). Subsequently, the template 
cDNA was used for a primary PCR for both G1m3 and G1m1 
allotyping. While the primary PCR is sufficient to account for 
G1m1,17 alleles, G1m3-allotyping required a secondary PCR to 
take account of (and exclude) isoallotypes that can be present in 
IgG3 and IgG4 regions. Primers and PCR programs are detailed 
in the supplementary section (Tables S1–S5 in Supplementary 
Material).
agarose gels
DNA products were separated by 1.2% agarose gel electrophoresis 
(100 V, 1 h) in 1× Tris acetate EDTA buffer. The agarose gel was 
stained with SYBR Safe (1 in 20,000), a suitable DNA ladder was 
loaded and 5× loading dye was added to each sample prior to 
loading the gel. DNA was visualized on a transilluminator.
elisa Protocol for igg1-allotyping
G1m3-ELISA
Serum antibodies from clinical trial participants were assessed 
for the presence of the IgG1-allotype G1m3 via a novel ELISA 
protocol adapted from a previously published ELISA platform 
(21). This antibody recognizes both the G1m3 allele prevalent in 
Caucasian populations and the G1m1,3 allele prevalent in those 
with Asian ancestry. In brief, 96-well high binding MaxiSorp 
plates (Nunc) were coated with 100  μl/well anti-G1m3 (Cat: 
I5385-0.2ML, Sigma, UK), at a 1:5,000 dilution in PBS, overnight 
at 4°C. As reference material, standard human Igs, which were 
captured with a combination of anti-human kappa (Southern 
Biotech, Cat: 2060-01) and lambda light chain (Cat: 2070-01) 
specific mouse antibodies, were used. These capture antibodies 
were coated onto the plates overnight at 4°C and coated plates 
were washed four times with PBS-T before blocking with PBS 
supplemented with 1%BSA and 0.05% Tween-20. Following fur-
ther washing, diluted serum samples were added to the precoated 
wells (generally between 1:10,000 and 1,000,000) and titrations of 
Ig standards were added to the kappa/lambda capture antibody 
coated wells at 50 μl/well and incubated for 1 h at 37°C. Plates 
were washed four times prior to the addition of antihuman IgG-
HRP and incubated for 1 h at 37°C. Plates were washed four times 
and developed with 50 μl/well of KPL SureBlue TMB substrate 
(Insight Biotechnology, UK). The reaction was stopped after 
5 min by adding 50 μl/well of 1 M H2SO4, and the absorbance 
read at 450 nm on a KC4 spectrophotometer.
G1m1 ELISA
For the G1m1 ELISA the commercially available detection anti-
body anti-IgG1-Hinge-HRP (Cat: 9052-08, Southern Biotech) 
was used at a 1:5,000 dilution. Except for the detection antibody, 
the G1m1-ELISA is identical to the anti-IgG1-ELISA protocol 
previously published (21). This antibody does not bind to G1m3 
allele, but does show cross reactivity with G1m1,3 allele prevalent 
in those with Asian ancestry, suggestive of recognition of the 
common G1m1 allotype.
customized Multiplex Dimer assay for the 
assessment of Fcr-Binding
A customized multivariate multiplex assay was developed using 
a panel of gp140 antigens (Clade C: CN54, 1086, Clade A: UG37, 
Clade D: UG21–NIH AIDS Reagents) covalently conjugated to 
different magnetic fluorescent multiplex beads (Bio-Rad, AU) 
as described previously (25). Biotinylated dimeric Fc-gamma-
Receptors (FcγRIIa-H131, FcγRIIIa-V158) were produced as 
previously described (26). The dimeric FcγR multiplex method 
has been previously published (21). Briefly, gp140 coupled 
microspheres (minimum 500 of each individual antigen bead 
set per well) was added to 1:100 plasma diluted in PBS + beads, 
incubating overnight at 4°C. HIVIG was used as a positive control 
to normalize across multiple replicates. Beads were washed using 
FigUre 1 | Assessment of IgG1-allotypes G1m3 and G1m1 in a cohort  
of HIV vaccine recipients via PCR and ELISA (n = 14). In the top chart 
OD-values for G1m3-specific signals (black bars) and G1m1-specific signals 
(green bars) are shown for X001 study participants (labeled 001–014). Shown 
are the mean (±SD) OD450-values of technical triplicates, representative of 
three replicates. OD-values greater than 0.5 were considered to be positive 
for the respective IgG1-allotype G1m3 and/or G1m1. The bottom panel 
shows the corresponding results from a novel PCR protocol, which was  
used to determine IgG1-allotypes from human RNA. Band sizes are 400 bp 
for G1m3 and 463 bp for G1m1 as indicated by the marker on the left.
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a Bio-Rad magnetic plate-washer (Bio-Plex Pro Wash station) 
and incubated for 2 h with biotinylated dimeric FcγR (1.0 μg/ml), 
then subsequently washed and incubated 1 h with streptavidin 
PE (1.0 μg/ml), washed again before resuspending in sheath fluid. 
A Bio-plex MAGPIX and Bio-Plex Manager software (Bio-Rad) 
was used to detect the median fluorescence intensity (MFI) for 
each bead set.
statistical Methods
Immunological analyses were based on the per protocol popula-
tion that received all vaccinations. Appropriate comparative sta-
tistics are annotated in the text and/or figure captions. Statistical 
analysis was carried out using Prism 7.0a (GraphPad, CA, USA) 
or the R software (R3.3.2) for statistical programming (27). The 
non-parametric Mann–Whitney test was used to compare two 
groups and the non-parametric Spearman’s rank correlation coef-
ficient was used to interrogate correlative relationships between 
the distributions of HIV-specific IgG1 levels and Fc-receptor 
binding in X001 study participants. p-Values ≤0.05 were consid-
ered significant (*p ≤ 0.05, **p ≤ 0.01, and ***p ≤ 0.001).
resUlTs
cross-Validation of a novel elisa 
Protocol for rapid igg1-allotyping  
against a Pcr Protocol
We wished to assess whether IgG-allotypes might be linked to 
differences in the IgG-subclass profile of Ag-specific antibody 
responses generated in the context of HIV-1 vaccination 
(28, 29). To pursue this, we developed novel PCR (Figure S1 in 
Supplementary Material) and ELISA protocols and combined 
them in a dual approach to determine the IgG1 allotype identity 
(G1m3 and/or G1m1) of clinical trial participants, using both 
human serum and mRNA. The optimized protocol was applied 
to determine the IgG1 allotype identity of 14 clinical trial par-
ticipants from an HIV vaccine study utilizing a Clade C gp140 
envelope protein (Figure 1; Figure S2 in Supplementary Material) 
(21). IgG1-allotyping X001 study participants revealed that 3/14 
(21%) were homozygous for G1m1 and 6/14 (43%) homozygous 
for G1m3, with 5/14 (36%) carrying both alleles (heterozygous). 
The IgG1 allotype abundance mirrors previously reported most 
frequent alleles representative of Caucasian population enrolled 
in this study (G1m3; G1m 17, 1; and G1m17,1,2), the concurring 
results demonstrate the interchangeability of the PCR and ELISA 
protocol for IgG1-allotyping. The clear cross-validation of both 
assays formats, allowed for the determination of the IgG1-allotype 
abundance in two additional clinical trials (23, 30), from which 
only serum samples were available (Figure S3 in Supplementary 
Material).
implications of igg1-allotypes for the 
analysis of hiV-Vaccine induce  
igg-subclass responses
The IgG1-allotype identities determined for the X001 study 
(21) provided a distinctive framework for the re-analysis of 
HIV vaccine-induced IgG-subclass profiles of the 11 per pro-
tocol individuals included in the full immunological analysis 
(Figure 2). Most participants, homo- or heterozygous for G1m1, 
exhibited a trend for higher Ag-specific IgG1 concentrations 
when compared to homozygous G1m3-carriers (Figure  2A). 
There was also a potential trend for homozygous G1m3-carriers 
to have greater Ag-specific IgG2 responses following the fourth 
immunization (Figure 2B). By contrast there were no identified 
differences in Ag-specific IgG3 and IgG4 responses according 
to G1m1 allotype (data not shown). Although the X001 study 
(21) was not powered sufficiently to demonstrate a statistical sig-
nificance between homologous G1m1- and G1m3-allele carriers, 
the apparent differences in Ag-specific IgG1/IgG2 levels warranted 
further investigation.
All participants with at least one G1m1-allele were then ana-
lyzed as a single group and directly compared with homozygous 
G1m3-carriers. The subsequent area under curve (AUC)-analysis 
across all time points helped to further unravel the effect of 
G1m1-allotypy on the magnitude of Ag-specific IgG1/IgG2 
responses by revealing trends and potential differences between 
G1m1-carriers and homologous G1m3-carriers (p  =  0.0823, 
Figure 2C). Furthermore, the highest Ag-specific IgG1 responses 
that occurred 14 days after the second IM and 14 days after the 
fourth IM were in G1m1-carriers (Figure 2A).
association of igg1-allotypes and 
Differences in ratios of antigen-specific 
igg1/igg2-levels following serial 
immunizations with cn54gp140
Following these initial observations, additional serum samples 
from the related MUCOVAC2 trial [EudraCT 2010-019103-27 
(23)] were made available for IgG1-allotyping (Figure S2 in 
Supplementary Material). MUCOVAC2 is a predecessor study to 
FigUre 2 | Individual antigen-specific IgG-subclass responses in the context of IgG1-allotypes. IgG-subclasses responses, classified with respect to G1m3 and/or 
G1m1 allotypes. (a) Individual Ag-specific IgG1-responses (participant IDs are shown in the legend on the right). (B) Individual Ag-specific IgG2-responses.  
(c) Area under curve (AUC) analysis for Ag-specific IgG1/IgG2 responses across all study time-points. Non-parametric Mann–Whitney test.
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X001 and was designed to establish the optimal route and dosage 
of immunization with the candidate HIV-1 clade C CN54gp140 
envelope glycoprotein vaccine (23). The timing (third IM, 
week8), immunogen (CN54gp140), and dose (100  μg) in the 
MUCOVAC2 trial was identical to week 8 (third IM) in the X001 
study. Thus, it was possible to pool data from the two clinical 
trials for this selected time point, allowing for a follow-up analysis 
of the differences in Ag-specific IgG1/IgG2 ratios mediated by 
G1m1 (Figure 3A: homozygous, n = 4; Figure 3B: homo- and/or 
heterozygous, n = 6) and G1m3 (homozygous, n = 7).
Following the 3-immunization priming phase, volunteers 
homozygous for G1m1 (n = 4) had fivefold higher Ag-specific 
IgG1/IgG2 ratios in comparison to homozygous G1m3-carriers 
(n = 7, p = 0.0242, Figure 3A). However, no significant differences 
in Ag-specific IgG1/IgG2 ratios were observed when comparing 
both hetero- and homozygous G1m1-carriers with homozygous 
G1m3-carriers when using this larger data set (p  =  0.1807, 
Figure 3B). It is important to note that the difference in IgG1/
IgG2 ratios when comparing homozygous G1m1 to G1m3 car-
riers likely reflects differences in magnitude of IgG1 responses, 
given there was little evidence for higher IgG2 responses at this 
time point (Figure 2B).
correlational relationships between 
Fcγr-Binding (Fcγriia/Fcγriiia) and  
ag-specific igg1 levels Were Determined 
with respect to Different combinations  
of g1m1 and/or g1m3 alleles
Despite statistical limitations in study power, evidence was found 
to suggest that Ag-specific IgG1/IgG2 levels varied according 
to the IgG1-allotype of the HIV-vaccine recipients. To further 
elucidate the role of allotypic variations in antibody responses, 
the impact of IgG1-allotypes on the magnitude of Fc-mediated 
functions was investigated. Investigating these observations in 
the context of an HIV-vaccine trial was facilitated by the use of 
a novel assay, using FcγR-ectodomains for probing Fc-mediated 
functions (26, 31). This assay was chosen based on the ease of 
standardization across laboratories in comparison to the varied 
cellular models of ADCC and ADCP function. Correlational 
FigUre 4 | HIV-specific IgG1 levels (x-axis) correlate with Fc-receptor binding in X001 study participants. Correlation analysis for X001 study participants across  
all study time-points. (a) homozygous G1m1-carriers, (B) homozygous G1m3-carriers, and (c) individuals heterozygous for G1m1/G1m3. Below the graph 
Spearman’s rank correlation coefficient r-values are shown (****p < 0.0001). MFI, median fluorescence intensity.
FigUre 3 | Differences in Ag-specific IgG1/IgG2 levels are associated with IgG1-allotypes after the third IM with CN54gp140. Presented data is from MUCOVAC2 
and X001 trials and is dose/time matched. (a) Differences in Ag-specific IgG1/IgG2 ratios between homozygous G1m1- and G1m3-carriers (+/+). (B) Differences  
in Ag-specific IgG1/IgG2 ratios between homo-/heterozygous G1m1- and homozygous G1m3-carriers (+/+). Non-parametric Mann–Whitney test (*p < 0.05).
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relationships between FcγR-binding (FcγRIIa/FcγRIIIa) and 
Ag-specific IgG1 levels were determined with respect to differ-
ent combinations of G1m1 and/or G1m3 alleles in X001 study 
participants (Figure  4; Figure S4 in Supplementary Material). 
The engagement of FcγRIIa/FcγRIIIa dimers via CN54gp140-
sepcifc serum antibodies correlated significantly (p <  0.0001) 
with Ag-specific IgG1 levels, irrespective of the IgG1-allotype 
combinations.
DiscUssiOn
A novel allotyping protocol was developed and employed to 
determine the abundance of IgG1-allotypes in HIV vaccine 
studies (X001 and MUCOVAC1 clinical trials). The allotype 
abundance was found to mirror those previously reported for 
Caucasian populations, in which the G1m3-allele is known to 
be predominant (10, 15, 32, 33). Interestingly, the frequency 
of donors homozygous for G1m3 (45.4%) reported for a larger 
study (570 community blood donors) coincided with the G1m3-
distribution determined for the X001 study (29). It is important 
to note that abundance of different G1m phenotypes and allotype 
differ in other ethnicities (e.g., Asian and African populations) 
for which many of the larger HIV vaccine trials are currently 
conducted, and these protocols will need to be confirmed in these 
ethnicities in the future.
Immunoglobulin G1 allotype analysis provided a framework 
for regrouping and reanalyzing the X001 Ag-specific IgG-
subclass data. Initial data analysis of individual Ag-specific IgG1 
responses in study participants suggested a link between G1m1-
carriers (homozygous or heterozygous) and elevated Ag-specific 
IgG1 responses when compared to homozygous G1m3-carriers. 
Thus, Ag-specific IgG1 concentrations from both homo- and 
heterozygous G1m1 carriers were grouped and compared with 
homozygous G1m3-carriers, revealing differences in Ag-specific 
IgG1 levels between the two study groups. The results align well 
with a previous study, in which different lower serum IgG and 
IgG-subclass levels were associated with G1m3, G3m5 allotypes 
in a study population of 157 Caucasian blood donors (34) and 
mirror the observations made by Lai et al. (7).
In contrast to this finding, HIV-1 vaccine recipients with at 
least one G1m1 allele appeared to have lower Ag-specific IgG2 
levels in comparison to homozygous G1m3-carriers following 
four immunizations. Subsequently, the Ag-specific IgG1:IgG2-
ratio was compared for time- and dose-matched samples from 
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two additional clinical HIV-vaccine trials. The data suggest 
that vaccinees homozygous for G1m1 have elevated Ag-specific 
IgG1:IgG2 ratios compared to G1m3-carriers. It is likely that 
this difference is predominantly driven by higher IgG1 levels 
associated with the G1m1 allele, any additional contribution of 
enhanced IgG2 levels associated with G1m3-carriers would need 
to be confirmed in larger studies. Interestingly, homozygosity for 
the G1m3-allele is strongly linked to the G2m23-allele in Northern 
Europe (9). Previous studies have suggested that individuals 
homozygous for this allotype (G2m23) exhibit higher serum 
IgG2 titers and decreased antipolysaccharide IgG2 responses than 
those homozygous for G2m(..), heterozygotes having intermedi-
ate levels (9, 12, 19, 35). Further work would be required to deter-
mine any additional contribution of G2m23 to the differences 
in IgG1:IgG2 ratios observed here.
Immunoglobulin G2 antibodies are generally associated with 
responses to carbohydrate antigens, which may be advantageous 
for recognizing ENV glycans (2), however, IgG2 has also been 
shown to recognize protein antigens. Indeed, two studies have 
demonstrated a link between IgG2 antibodies to HIV Gag pro-
teins and natural control of HIV infection (36, 37). Nevertheless, 
a related study failed to detect differences in Gag-specific IgG2 
levels between HIV controllers and chronic progressors (20). 
However, in contrast to the two studies, that used viral lysates in 
Western blot assays, Banerjee et al. (20) used recombinant HIV 
antigens in ELISAs, implying that conformational variations in 
HIV antigen could have affected IgG2-detection (20).
Observations in this study that elevated levels of HIV-
specific IgG1 and decreased IgG2 levels were associated with 
the G1m17-allele, support the hypothesis that allotypes could 
present useful Gms for the assessment of HIV-1 acquisition 
risk in vaccinated individuals. This concept was first tested on 
samples from the Step Study (17), that failed to show protec-
tive efficacy. This phase IIb proof-of-concept study, designed to 
assess the efficacy of the MRK Ad5 gag/pol/nef HIV vaccine, 
was terminated prematurely on the grounds of futility. However, 
there was an observed increased risk of HIV-1 acquisition in the 
vaccine group when compared to the placebo group (38, 39). 
Pandey et al. (17) went on to investigate whether this observed 
increased risk of HIV-1 acquisition could be linked to Ig allotype 
and revealed that the risk of HIV-1 acquisition was significantly 
increased in individuals positive for a combination of homozy-
gous G1m17 and Km1 allotypes. Furthermore, the researchers 
found that subjects homozygous for FcγRIIIa (F-version) in 
the absence of G2m23 were more likely to become infected 
with HIV-1 (17). The significance of these findings in terms of 
immune function are unclear given the vaccine approach was 
predicated on eliciting cellular responses designed to control 
viral replication rather than protective antibodies. Nevertheless, 
they serve to highlight the potential association of Ig allotype 
with HIV acquisition.
In the present study, we applied a novel assay for probing 
the engagement of FcγRIIa/FcγRIIIa dimers to investigate 
potential links between IgG1-allotypy and Fc-effector binding 
profiles (26). This has potential implications for HIV vaccine 
research since the significance of Fc-effector functions has been 
highlighted by a large phase III HIV-vaccine trial (RV144), 
in which HIV-specific ADCC was associated with enhanced 
protection against HIV-1 acquisition (40, 41). A similar vaccine 
approach is now being pursued in the HVTN 702 trail evaluated 
in South Africa. The potential for IgG1 allotype to influence 
ADCC function is not without precedent, previously reported 
in prostate cancer where the capacity of NK  cells to mediate 
ADCC against prostate cancer cells is influenced by interac-
tions between different IgG1-allotypes and the corresponding 
FcγRIIIa variants (28). Similar to the RV144, we determined 
the interactions of serum antibodies specific to different HIV-1 
clades, with FcγRIIa/FcγRIIIa-dimers and with respect to the 
IgG1-allotypes G1m1 and G1m3. Higher titers of FcγR-dimer 
binding by CN54gp140-specific serum antibodies were detected 
in G1m1-carriers as opposed to homozygous G1m3 carriers. 
Increased IgG1-titers that were associated with G1m1 are likely 
responsible for augmented binding of FcγR dimers given the 
higher affinity of IgG1 over IgG2. Indeed, IgG1 titers directly 
correlated with FcγR-binding irrespective of allotype (Figure 4). 
This trend for increased FcγR-dimer binding in G1m1-carriers 
by vaccine-induced serum antibodies was generally preserved 
against envelope proteins of different HIV-1 clades, implying 
that epistatic interactions between Fc-domains and FcγR could 
play an important role in HIV-1 vaccines. This notion is sup-
ported by another study that investigated the abundance of FcγR 
and Gm allotypes among HIV-1 controllers and non-controllers. 
The major finding was that among Caucasian Americans nega-
tive for the FcγRIIa allele, Gm21-positive individuals were seven 
times more likely to be HIV-1 controllers than non-carriers 
of Gm21, whereas this trend was not observed in the African 
American cohort (42). It would be interesting to investigate at 
the sequence level, if similar links could be found for G1m3 and 
G1m1 allotypes in HIV-1 vaccine recipients.
Although the results of this study are preliminary, they suggest 
that individuals homozygous for G1m3 exhibit lower levels of 
Ag-specific IgG1 and as a consequence lower FcγR-engagement 
in response to HIV-vaccination. If FcγR function is important for 
antibody-mediated protection then these individuals would be 
less well protected than those homozygous for G1m1. These results 
have important implications for the two ongoing efficacy studies 
of HIV vaccines (HVTN 702 and 705) predicated on engagement 
of FcγR-mediated cellular functions including ADCC and ADCP. 
Our novel allotyping protocol provides new tools to determine 
the potential impact of IgG1 allotypes on vaccine efficacy.
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